We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Pfizer (PFE) Stock Sinks As Market Gains: What You Should Know
Read MoreHide Full Article
Pfizer (PFE - Free Report) ended the recent trading session at $26.80, demonstrating a -1.87% change from the preceding day's closing price. This change lagged the S&P 500's daily gain of 1.05%. Elsewhere, the Dow gained 0.69%, while the tech-heavy Nasdaq added 1.64%.
The drugmaker's shares have seen an increase of 1.3% over the last month, surpassing the Medical sector's gain of 0.31% and falling behind the S&P 500's gain of 8.59%.
The upcoming earnings release of Pfizer will be of great interest to investors. The company's earnings report is expected on May 5, 2026. In that report, analysts expect Pfizer to post earnings of $0.74 per share. This would mark a year-over-year decline of 19.57%. In the meantime, our current consensus estimate forecasts the revenue to be $13.82 billion, indicating a 0.77% growth compared to the corresponding quarter of the prior year.
PFE's full-year Zacks Consensus Estimates are calling for earnings of $2.98 per share and revenue of $61.11 billion. These results would represent year-over-year changes of -7.45% and -2.35%, respectively.
Investors should also take note of any recent adjustments to analyst estimates for Pfizer. These recent revisions tend to reflect the evolving nature of short-term business trends. Therefore, positive revisions in estimates convey analysts' confidence in the business performance and profit potential.
Our research suggests that these changes in estimates have a direct relationship with upcoming stock price performance. To capitalize on this, we've crafted the Zacks Rank, a unique model that incorporates these estimate changes and offers a practical rating system.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. The Zacks Consensus EPS estimate has moved 0.31% higher within the past month. Pfizer is currently sporting a Zacks Rank of #3 (Hold).
Investors should also note Pfizer's current valuation metrics, including its Forward P/E ratio of 9.16. This expresses a discount compared to the average Forward P/E of 14.36 of its industry.
The Large Cap Pharmaceuticals industry is part of the Medical sector. At present, this industry carries a Zacks Industry Rank of 168, placing it within the bottom 32% of over 250 industries.
The Zacks Industry Rank is ordered from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
Pfizer (PFE) Stock Sinks As Market Gains: What You Should Know
Pfizer (PFE - Free Report) ended the recent trading session at $26.80, demonstrating a -1.87% change from the preceding day's closing price. This change lagged the S&P 500's daily gain of 1.05%. Elsewhere, the Dow gained 0.69%, while the tech-heavy Nasdaq added 1.64%.
The drugmaker's shares have seen an increase of 1.3% over the last month, surpassing the Medical sector's gain of 0.31% and falling behind the S&P 500's gain of 8.59%.
The upcoming earnings release of Pfizer will be of great interest to investors. The company's earnings report is expected on May 5, 2026. In that report, analysts expect Pfizer to post earnings of $0.74 per share. This would mark a year-over-year decline of 19.57%. In the meantime, our current consensus estimate forecasts the revenue to be $13.82 billion, indicating a 0.77% growth compared to the corresponding quarter of the prior year.
PFE's full-year Zacks Consensus Estimates are calling for earnings of $2.98 per share and revenue of $61.11 billion. These results would represent year-over-year changes of -7.45% and -2.35%, respectively.
Investors should also take note of any recent adjustments to analyst estimates for Pfizer. These recent revisions tend to reflect the evolving nature of short-term business trends. Therefore, positive revisions in estimates convey analysts' confidence in the business performance and profit potential.
Our research suggests that these changes in estimates have a direct relationship with upcoming stock price performance. To capitalize on this, we've crafted the Zacks Rank, a unique model that incorporates these estimate changes and offers a practical rating system.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. The Zacks Consensus EPS estimate has moved 0.31% higher within the past month. Pfizer is currently sporting a Zacks Rank of #3 (Hold).
Investors should also note Pfizer's current valuation metrics, including its Forward P/E ratio of 9.16. This expresses a discount compared to the average Forward P/E of 14.36 of its industry.
The Large Cap Pharmaceuticals industry is part of the Medical sector. At present, this industry carries a Zacks Industry Rank of 168, placing it within the bottom 32% of over 250 industries.
The Zacks Industry Rank is ordered from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.